As several glioma-associated antigens (GAAs) are now known, it becomes possible to expand CD8+ T cells against these GAA, giving the possibility to treat patient even when tumour cells are not available, but also allowing genetic modifications of the autologous lymphocytes [87]. This evidence concerns the gene CD8A and glioma.